Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3767 - Bioinformatic estimate of biomarker-positive populations in Genomics-driven trials using Precision Trial Designer (PTD)

Date

11 Sep 2017

Session

Poster display session

Presenters

Luca Mazzarella

Citation

Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363

Authors

L. Mazzarella1, G. Melloni2, A. Guida1, G. Curigliano1, E. Botteri3, A. Esposito1, M. Kamal4, C. Le Tourneau4, L. Riva5, P. Pelicci6

Author affiliations

  • 1 New Drug Development, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 2 Biomedical Informatics, Harvard Medical School, 02115 - Boston/US
  • 3 Norwegian National Advisory Unit On Women's Health, Oslo University Hosp., 0424 - Oslo/NO
  • 4 Dept Of Medical Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 5 Center For Genomic Science, Italian Institute of Technology, 20141 - Milan/IT
  • 6 Department Of Experimental Oncology, European Institute of Oncology, 20139 - Milan/IT
More

Resources

Abstract 3767

Background

Trials that prospectively accrue based on genetics are powerful methods to test hypotheses in precision oncology, but are often difficult to conduct due to the rarity of biomarker-positive cases. This is mitigated in umbrella trials that maximize accrual by testing many hypotheses. However, multiple treatment arms frequently generate conflicting treatment allocations due to simultaneous actionable mutations; the allocation algorithm should be planned based on relative mutation frequencies to accurately estimate sample size and dropout rates. Large sequencing projects like the TCGA could be exploited but proper tools are lacking.

Methods

We developed Precision Trial Designer (PTD), a bioinformatic tool that simulates genomically-defined cohorts by iteratively sampling patient data from mutation databases (e.g. TCGA) and provides essential parameters to plan biomarker-driven trials using survival or response-rate endpoints. To show its potential, we simulated a 10-arm imaginary trial on multiple cancers, based on the Molecular Analyses for Personalized medicine (MAP) consensus. We then validated our approach by comparing simulated and real data from the SHIVA01 clinical trial.

Results

In the MAP trial, PTD predicted ≥1 actionable alteration in 73% patients and 32% conflicts. To adequately power each arm, we found the optimal rule that maximizes accrual (ALK inhibitors first, AKT inhibitors last) and propose various designs. In the SHIVA01 simulation, combinatorial point mutations were correctly predicted (18.9%, 95%CI 15.7-22.1 simulated vs 15.3%, 11.8-18.7 real), whereas PTD slightly overestimated copy number alterations (36.3%, 31.6-41 simulated vs 25.6%, 21.4-29.7 real), a predictable gap due to different detection techniques. Overall, 50.8% (46.2-55.7) cases were predicted as biomarker-positive, vs 37% (32.5-41.7) real. The relative contribution of each pathway of treatment (RAS/MEK, PI3K/MTOR) was conserved (47.8%, 41.7-53.9 and 25.8%, 19.9-31.5 simulated vs 53.1%, 95%CI 48.3-57.9 and 31.6%, 27.2-36.1 real, respectively).

Conclusions

PTD predicts combinatorial mutation frequencies with acceptable approximation and overcomes pressing issues in designing precision trials.

Clinical trial identification

Legal entity responsible for the study

Luca Mazzarella

Funding

This research was funded by an AIRC Investigator Grant to G Curigliano and by grant ANR-10-EQPX-03 from the Agence Nationale de le Recherche (Investissements d’avenir) and SiRIC (Site de Recherche Intégré contre le Cancer).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.